https://www.thefrancejournal.com/article/907745648-hitechmoda-builds-a-global-stage-for-the-next-big-names-in-fashion The France Journal en PressRelease 2026-04-24T16:00:00+00:00 hiTechMODA Builds a Global Stage for the Next Big Names in Fashion https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/22418639-logo-hitechmoda-766x189.png https://www.thefrancejournal.com/article/905963305-theom-redefines-ai-data-security-placing-as-a-leader-across-major-industry-analyst-evaluations The France Journal en PressRelease 2026-04-24T15:51:15+00:00 Theom Redefines AI & Data Security, Placing as a Leader Across Major Industry Analyst Evaluations https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24838636-logo-with-tagline-4050x1796.png https://www.thefrancejournal.com/article/907755397-parisian-engineer-wins-1941-picasso-as-charity-raffle-raises-12m-for-alzheimer-s-research-at-christie-s-drawing The France Journal en PressRelease 2026-04-24T15:26:54+00:00 Parisian Engineer Wins 1941 Picasso as Charity Raffle Raises €12M for Alzheimer’s Research at Christie’s Drawing https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24811172-1-picasso-for-100-euros-544x676.jpeg https://www.thefrancejournal.com/article/907510118-french-edm-artist-apotiker-explores-music-s-role-in-emotional-well-being-with-upcoming-releases The France Journal en PressRelease 2026-04-24T14:48:26+00:00 French EDM Artist Apotiker Explores Music’s Role in Emotional Well-Being with Upcoming Releases https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24839279-apotiker-1190x1192.png https://www.thefrancejournal.com/article/907695173-awaji-island-in-japan-tv-anime-attack-on-titan-nijigen-no-mori-collaboration-day-event-attack-on-titan-mystery-quest The France Journal en PressRelease 2026-04-24T13:00:00+00:00 Awaji Island in Japan TV Anime Attack on Titan × Nijigen no Mori Collaboration Day Event 'Attack on Titan Mystery Quest' https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24840161-tv-anime-attack-on-titan-coll-1200x849.jpeg https://www.thefrancejournal.com/article/907833353-press-release-sanofi-successfully-prices-2-3-billion-of-bond-issue The France Journal en PressRelease 2026-04-24T18:30:00+00:00 Press Release: Sanofi successfully prices 2.3 billion of bond issue https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.thefrancejournal.com/article/907833358-communiqu-de-presse-sanofi-place-2-3-milliard-d-euros-d-emprunts-obligataires The France Journal en PressRelease 2026-04-24T18:30:00+00:00 Communiqué de presse : Sanofi place 2,3 milliard d’euros d’emprunts obligataires https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.thefrancejournal.com/article/901822657-charlie-jbeily-met-en-lumi-re-la-strat-gie-mondiale-de-xs-com-en-mati-re-de-talents-dans-une-interview-pour-gamechangers The France Journal en PressRelease 2026-04-24T05:24:49+00:00 Charlie Jbeily met en lumière la stratégie mondiale de XS.com en matière de talents dans une interview pour GameChangers https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24839401-24-04-charlie-jbeily-s-interv-500x500.jpeg https://www.thefrancejournal.com/article/907740410-ai-technology-virtual-investor-conference-presentations-now-available-for-online-viewing The France Journal en PressRelease 2026-04-24T12:35:00+00:00 AI & Technology Virtual Investor Conference: Presentations Now Available for Online Viewing https://ml.globenewswire.com/media/861fb541-7064-4cf4-a563-37472ff71760/small/social-media-vic-announcment-2-png.png https://www.thefrancejournal.com/article/907742448-orientalischer-schmuck-gl-nzt-an-der-seine-chinas-perlenzentrum-zhuji-wirbt-in-paris-f-r-stadt-und-industrie The France Journal en PressRelease 2026-04-24T11:56:48+00:00 Orientalischer Schmuck glänzt an der Seine: Chinas Perlenzentrum Zhuji wirbt in Paris für Stadt und Industrie https://ml.globenewswire.com/media/YmE3NGMyNzEtZGEyNi00YmYwLWI4ZWUtNWJmYjk2MDM5OWExLTUwMDE2MTU1OC0yMDI2LTA0LTI0LWRl/tiny/Zhejiang-Pearl-Industry-Associ.png https://www.thefrancejournal.com/article/907742453-bijoux-orientaux-l-honneur-sur-les-bords-de-seine-la-ville-de-zhuji-centre-perlier-chinois-promeut-son-patrimoine-et-son-industrie-paris The France Journal en PressRelease 2026-04-24T11:56:48+00:00 Bijoux orientaux à l’honneur sur les bords de Seine : la ville de Zhuji, centre perlier chinois, promeut son patrimoine et son industrie à Paris https://ml.globenewswire.com/media/YmE3NGMyNzEtZGEyNi00YmYwLWI4ZWUtNWJmYjk2MDM5OWExLTUwMDE2MTU1OC0yMDI2LTA0LTI0LWZy/tiny/Zhejiang-Pearl-Industry-Associ.png https://www.thefrancejournal.com/article/907715752-press-release-sanofi-s-cenrifki-tolebrutinib-recommended-for-eu-approval-by-the-chmp-to-treat-secondary-progressive-multiple-sclerosis-without The France Journal en PressRelease 2026-04-24T10:09:31+00:00 Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.thefrancejournal.com/article/907715819-communiqu-de-presse-cenrifki-de-sanofi-tolebrutinib-recommand-par-le-comit-des-m-dicaments-usage-humain-cmuh-pour-tre-approuv-par-l-ue The France Journal en PressRelease 2026-04-24T10:09:31+00:00 Communiqué de presse : Cenrifki de Sanofi (tolebrutinib) recommandé par le Comité des médicaments à usage humain (CMUH) pour être approuvé par l’UE pour le traitement de la sclérose en plaques secondairement progressive sans poussées https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.thefrancejournal.com/article/907693920-exel-industries-q2-2025-2026-revenue-12-1 The France Journal en PressRelease 2026-04-24T06:07:00+00:00 EXEL Industries: Q2 2025–2026 revenue -12.1% https://ml-eu.globenewswire.com/media/4e718614-9f06-4606-8441-e92f5c79ab74/small/logo-exel-png.png https://www.thefrancejournal.com/article/907693953-exel-industries-chiffre-d-affaires-2e-trimestre-2025-2026-12-1 The France Journal en PressRelease 2026-04-24T06:07:00+00:00 EXEL Industries : Chiffre d’affaires 2e trimestre 2025–2026 -12,1% https://ml-eu.globenewswire.com/media/4e718614-9f06-4606-8441-e92f5c79ab74/small/ https://www.thefrancejournal.com/article/907567405-american-management-university-expands-access-to-learning-through-60-free-e-certificate-programs-available-worldwide The France Journal en PressRelease 2026-04-23T18:03:11+00:00 American Management University Expands Access to Learning Through 60+ Free E-Certificate Programs Available Worldwide https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/5494719-wall-mock-up-4000x2667.jpeg https://www.thefrancejournal.com/article/907521066-les-produits-de-la-mer-britanniques-mettent-en-avant-leurs-atouts-au-seafood-expo-global The France Journal en PressRelease 2026-04-23T14:40:43+00:00 Les produits de la mer britanniques mettent en avant leurs atouts au Seafood Expo Global https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24839372-seaf1-1096x730.jpeg https://www.thefrancejournal.com/article/907333521-vera-co-founder-julie-cropp-gareleck-featured-as-a-leading-voice-on-people-first-ai-and-workforce-transformation The France Journal en PressRelease 2026-04-23T10:00:00+00:00 Vera Co-Founder Julie Cropp Gareleck Featured as a Leading Voice on People-First AI and Workforce Transformation https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/23803362-vera-corporate-company-logo-3333x2500.jpeg https://www.thefrancejournal.com/article/907567508-vantiva-first-quarter-2026-sales-and-refinancing The France Journal en PressRelease 2026-04-23T17:03:00+00:00 Vantiva - First Quarter 2026 Sales and Refinancing https://ml-eu.globenewswire.com/media/a1774cf2-0a53-4c3c-8c80-6dff1dff7bd3/small/vantiva-logo-with-tagline-512x384-1-png.png https://www.thefrancejournal.com/article/907567539-vantiva-chiffre-d-affaires-du-premier-trimestre-et-refinancement The France Journal en PressRelease 2026-04-23T17:03:00+00:00 Vantiva - Chiffre d’affaires du premier trimestre et refinancement https://ml-eu.globenewswire.com/media/a1774cf2-0a53-4c3c-8c80-6dff1dff7bd3/small/vantiva-logo-with-tagline-512x384-1-png.png https://www.thefrancejournal.com/article/907567352-vantiva-results-full-year-2025 The France Journal en PressRelease 2026-04-23T17:00:00+00:00 Vantiva - Results Full Year 2025 https://ml-eu.globenewswire.com/media/a1774cf2-0a53-4c3c-8c80-6dff1dff7bd3/small/vantiva-logo-with-tagline-512x384-1-png.png https://www.thefrancejournal.com/article/907567440-vantiva-r-sultats-annuels-2025 The France Journal en PressRelease 2026-04-23T17:00:00+00:00 Vantiva - Résultats annuels 2025 https://ml-eu.globenewswire.com/media/a1774cf2-0a53-4c3c-8c80-6dff1dff7bd3/small/vantiva-logo-with-tagline-512x384-1-png.png https://www.thefrancejournal.com/article/907567137-alliance-developpement-capital-siic-communiqu-sur-les-r-sultats-au-31-d-cembre-2025 The France Journal en PressRelease 2026-04-23T16:17:43+00:00 ALLIANCE DEVELOPPEMENT CAPITAL SIIC: Communiqué sur les résultats au 31 décembre 2025 https://ml-eu.globenewswire.com/media/8664cbf6-d86b-47c0-a845-52067ee079be/small/ https://www.thefrancejournal.com/article/907566642-chiffre-d-affaires-du-1er-trimestre-2026 The France Journal en PressRelease 2026-04-23T15:45:00+00:00 Chiffre d’affaires du 1er trimestre 2026 https://ml-eu.globenewswire.com/media/c4731c25-21f2-47d1-910e-edbaeb4de604/small/ https://www.thefrancejournal.com/article/907566874-q1-2026-revenue The France Journal en PressRelease 2026-04-23T15:45:00+00:00 Q1 2026 revenue https://ml-eu.globenewswire.com/media/c4731c25-21f2-47d1-910e-edbaeb4de604/small/logo-color-cmjn-bd-jpg.jpg https://www.thefrancejournal.com/article/907566930-sword-group-q1-2026-results The France Journal en PressRelease 2026-04-23T15:35:00+00:00 Sword Group | Q1 2026 Results https://ml-eu.globenewswire.com/media/90954a41-96fb-4c61-8aae-db340cec7382/small/logo-sword-cmyk-png.png https://www.thefrancejournal.com/article/907566966-sword-group-r-sultats-du-1er-trimestre-2026 The France Journal en PressRelease 2026-04-23T15:35:00+00:00 Sword Group | Résultats du 1er trimestre 2026 https://ml-eu.globenewswire.com/media/90954a41-96fb-4c61-8aae-db340cec7382/small/ https://www.thefrancejournal.com/article/907549770-blacknut-levels-up-select-activision-publishing-and-blizzard-entertainment-games-now-streamable-on-blacknut The France Journal en PressRelease 2026-04-23T15:15:00+00:00 Blacknut Levels Up: Select Activision Publishing and Blizzard Entertainment Games Now Streamable on Blacknut https://ml.globenewswire.com/media/ZWU5OWVkMGEtZWFlZC00MTc5LTlkZjItYzc1MjBhZmQwMDdkLTEyNTc1NzEtMjAyNi0wNC0yMy1lbg==/tiny/Blacknut.png https://www.thefrancejournal.com/article/907526322-stmicroelectronics-organise-une-conf-rence-investisseurs-sur-l-opportunit-leo The France Journal en PressRelease 2026-04-23T13:00:00+00:00 STMicroelectronics organise une conférence investisseurs sur l’opportunité LEO https://ml-eu.globenewswire.com/media/281fbc38-04be-49ef-832b-48f4f2f8c959/small/ https://www.thefrancejournal.com/article/907526668-stmicroelectronics-to-host-investor-call-on-the-leo-opportunity The France Journal en PressRelease 2026-04-23T13:00:00+00:00 STMicroelectronics to host investor call on the LEO opportunity https://ml-eu.globenewswire.com/media/281fbc38-04be-49ef-832b-48f4f2f8c959/small/st-logo-2024-blue-jpg.jpg https://www.thefrancejournal.com/article/907526756-arcelormittal-announces-the-publication-of-its-first-quarter-2026-sell-side-analyst-consensus-figures The France Journal en PressRelease 2026-04-23T13:00:00+00:00 ArcelorMittal announces the publication of its first quarter 2026 sell-side analyst consensus figures https://ml-eu.globenewswire.com/media/b63cd58c-c7c3-4ece-b5f9-2f69f23244cd/small/logo-jpg.jpg https://www.thefrancejournal.com/article/907538436-oriental-jewelry-shine-by-the-seine-china-s-pearl-hub-zhuji-promotes-city-industry-in-paris The France Journal en PressRelease 2026-04-23T13:00:00+00:00 Oriental Jewelry Shine by the Seine: China's Pearl Hub Zhuji Promotes City, Industry in Paris https://ml.globenewswire.com/media/MjQ1NGI3OGUtNGRhYS00MzM0LTlkYWEtNzhlYWI1ODY1ODU4LTUwMDE2MTU1OC0yMDI2LTA0LTIzLWVu/tiny/Zhejiang-Pearl-Industry-Associ.png https://www.thefrancejournal.com/article/907531852-international-companies-to-host-live-webcasts-at-deutsche-bank-s-depositary-receipts-virtual-investor-conference-on-april-28-2026 The France Journal en PressRelease 2026-04-23T12:35:00+00:00 International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026 https://ml.globenewswire.com/media/861fb541-7064-4cf4-a563-37472ff71760/small/social-media-vic-announcment-2-png.png https://www.thefrancejournal.com/article/907490040-last-patient-last-visit-completed-in-phase-i-clinical-trial-of-pulsesight-therapeutics-pst-611-treatment-for-dry-amd-geographic-atrophy-ga The France Journal en PressRelease 2026-04-23T07:00:00+00:00 Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA) https://ml-eu.globenewswire.com/media/9f8ee53c-2465-4c3c-870e-4077c6a39edb/small/pulsesight-therapeutics-logo-horizontal-full-gradient-mark-0.png https://www.thefrancejournal.com/article/907473569-arcelormittal-publishes-its-2025-sustainability-report-safer-smarter-growth The France Journal en PressRelease 2026-04-23T06:30:00+00:00 ArcelorMittal publishes its 2025 Sustainability Report: Safer, smarter growth https://ml-eu.globenewswire.com/media/b63cd58c-c7c3-4ece-b5f9-2f69f23244cd/small/logo-jpg.jpg https://www.thefrancejournal.com/article/907472537-ose-immunotherapeutics-annonce-la-pr-sentation-des-r-sultats-de-l-tude-de-phase-2-tedova-de-tedopi-dans-le-cancer-de-l-ovaire-au-congr-s-2026-de The France Journal en PressRelease 2026-04-23T05:30:00+00:00 OSE Immunotherapeutics annonce la présentation des résultats de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire au Congrès 2026 de l’ASCO https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ https://www.thefrancejournal.com/article/907472704-communiqu-de-presse-t1-2026-croissance-deux-chiffres-du-chiffre-d-affaires-et-du-bnpa The France Journal en PressRelease 2026-04-23T05:30:00+00:00 Communiqué de presse : T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.thefrancejournal.com/article/907472829-ose-immunotherapeutics-announces-presentation-of-tedova-phase-2-topline-results-of-tedopi-in-ovarian-cancer-at-the-asco-2026-meeting The France Journal en PressRelease 2026-04-23T05:30:00+00:00 OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ose-logo-horizontal-rvb-png.png https://www.thefrancejournal.com/article/907472887-eramet-strong-turnover-momentum-in-q1-2026-driven-by-a-solid-operational-performance The France Journal en PressRelease 2026-04-23T05:30:00+00:00 Eramet: strong turnover momentum in Q1 2026 driven by a solid operational performance https://ml-eu.globenewswire.com/media/39e0e6de-e61c-466c-8714-84980b493551/small/logo-jpg.jpg https://www.thefrancejournal.com/article/907472891-eramet-croissance-soutenue-du-chiffre-d-affaires-au-1er-trimestre-2026-port-e-par-une-bonne-performance-op-rationnelle The France Journal en PressRelease 2026-04-23T05:30:00+00:00 Eramet : croissance soutenue du chiffre d’affaires au 1er trimestre 2026 portée par une bonne performance opérationnelle https://ml-eu.globenewswire.com/media/39e0e6de-e61c-466c-8714-84980b493551/small/ https://www.thefrancejournal.com/article/907473075-press-release-q1-2026-double-digit-sales-and-business-eps-growth The France Journal en PressRelease 2026-04-23T05:30:00+00:00 Press Release: Q1 2026: double-digit sales and business EPS growth https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.thefrancejournal.com/article/907472404-nokia-oyj-n-vuoden-2026-ensimm-isen-nelj-nneksen-osavuosikatsaus The France Journal en PressRelease 2026-04-23T05:00:00+00:00 Nokia Oyj:n vuoden 2026 ensimmäisen neljänneksen osavuosikatsaus https://ml-eu.globenewswire.com/media/e6523d78-c43a-4057-8aa9-68206d3af4a8/small/nokialogo-png.png https://www.thefrancejournal.com/article/907472574-nokia-corporation-interim-report-for-q1-2026 The France Journal en PressRelease 2026-04-23T05:00:00+00:00 Nokia Corporation Interim Report for Q1 2026 https://ml-eu.globenewswire.com/media/e6523d78-c43a-4057-8aa9-68206d3af4a8/small/nokialogo-png.png https://www.thefrancejournal.com/article/907472844-stmicroelectronics-annonce-ses-r-sultats-financiers-du-premier-trimestre-2026 The France Journal en PressRelease 2026-04-23T05:00:00+00:00 STMicroelectronics annonce ses résultats financiers du premier trimestre 2026 https://ml-eu.globenewswire.com/media/281fbc38-04be-49ef-832b-48f4f2f8c959/small/ https://www.thefrancejournal.com/article/907473115-ipsen-delivers-strong-sales-in-the-first-quarter-of-2026-and-confirms-its-full-year-guidance The France Journal en PressRelease 2026-04-23T05:00:00+00:00 Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ipsen-notified-website-1200x628pix-500kb-max-jpg.jpg https://www.thefrancejournal.com/article/907473136-ipsen-enregistre-une-forte-croissance-de-ses-ventes-au-premier-trimestre-2026-et-confirme-ses-objectifs-annuels The France Journal en PressRelease 2026-04-23T05:00:00+00:00 Ipsen enregistre une forte croissance de ses ventes au premier trimestre 2026 et confirme ses objectifs annuels https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ https://www.thefrancejournal.com/article/907473213-stmicroelectronics-reports-q1-2026-financial-results The France Journal en PressRelease 2026-04-23T05:00:00+00:00 STMicroelectronics Reports Q1 2026 Financial Results https://ml-eu.globenewswire.com/media/281fbc38-04be-49ef-832b-48f4f2f8c959/small/st-logo-2024-blue-jpg.jpg https://www.thefrancejournal.com/article/907473244-worldwide-clinical-trials-and-medidata-announce-strategic-partnership-to-embed-medidata-ai-across-the-full-trial-lifecycle-bolstering-study-execution The France Journal en PressRelease 2026-04-23T05:00:00+00:00 Worldwide Clinical Trials and Medidata Announce Strategic Partnership to Embed Medidata AI Across the Full Trial Lifecycle, Bolstering Study Execution and Delivery Excellence https://ml.globenewswire.com/media/a26f92c9-b08f-4530-a70f-6dec8dee7e36/small/3ds-medidata-logotype-navy-1-jpg.jpg https://www.thefrancejournal.com/article/907404570-press-release-sanofi-and-regeneron-s-dupixent-approved-in-the-us-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic The France Journal en PressRelease 2026-04-22T21:30:00+00:00 Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.thefrancejournal.com/article/907404644-communiqu-de-presse-dupixent-d-velopp-par-sanofi-et-regeneron-a-t-approuv-aux-tats-unis-comme-tant-le-premier-m-dicament-biologique-pour The France Journal en PressRelease 2026-04-22T21:30:00+00:00 Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.thefrancejournal.com/article/907406205-dupixent-dupilumab-approved-in-the-u-s-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria-csu The France Journal en PressRelease 2026-04-22T21:30:00+00:00 Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU) https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg